Cargando…
PARP inhibitor-related haemorrhages: What does the real-world study say?
BACKGROUND: PARP inhibitors (PARPis) are novel molecular targeted therapeutics for inhibition of DNA repair in tumor cells, which are commonly used in ovarian cancer. Recent case reports have indicated that haemorrhages-related adverse events may be associated with PARPis. However, little is known a...
Autores principales: | Wang, Shiyan, Guo, Mengran, Zhang, Xiang, Fan, Ping, Jin, Zhaohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008930/ https://www.ncbi.nlm.nih.gov/pubmed/36923428 http://dx.doi.org/10.3389/fonc.2023.1070343 |
Ejemplares similares
-
What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
por: Zhang, Depu, et al.
Publicado: (2022) -
What the Insurance World Say
Publicado: (1888) -
A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023) -
What investors say is what the market says: measuring China’s real investor sentiment
por: Sun, Yunchuan, et al.
Publicado: (2021) -
PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)